An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (KRT-232-101)

  • Perkins, Andrew (Primary Chief Investigator (PCI))
  • Ross, David Morrall (Chief Investigator (CI))
  • Kennedy, Nola (Project Manager)
  • Yeh, Paul (Partner Investigator (PI))
  • Wright, Matthew (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date20/01/2031/12/25


  • Malignant Haematology
  • Primary Myelofibrosis
  • Clinical trial